Cytochroma Appoints R. Richard Wieland...(ed to grow significantlyreaching more th...)

Date:5/12/2008

ed to grow significantly, reaching more than $1.2 billion annually by 2010 in North America alone. Cytochroma has three lead product candidates in development for CKD patients: CTA018 and CTAP201 are being developed for the treatment of secondary hyperparathyroidism (SHPT), while CTAP101 is being developed for the treatment of Vitamin D insufficiency.

About Chronic Kidney Disease

According to the National Kidney Foundation (NKF), more than nine million North American patients suffer from moderate CKD (Stages 3 and 4) to severe CKD (Stage 5). Stages 3 and 4 are characterized by progressively decreasing kidney function as measured by glomerular filtration rate. In Stage 5, kidney function is altogether absent and patients require regular dialysis or kidney transplant for survival. An estimated 70-90% of CKD patients have Vitamin D insufficiency, which can lead to SHPT and resultant debilitating bone diseases. Mounting evidence continues to link Vitamin D insufficiency with CKD progression and increased morbidity and mortality in CKD patients. CKD is most frequently caused by diabetes or hypertension, both of which are consequences of a growing obesity epidemic in countries worldwide.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of Vitamin D insufficiency and SHPT associated with CKD. The Company's Vitamin D-based therapeutics are designed to safely and effectively treat patients with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in these same patients. For more information, please visit http://www.cytochroma.com.

'/>"/>

SOURCE Cytochroma Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
2. Cytochroma opens U.S. headquarters in Illinois
3. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
4. Codexis Appoints Singapore Laboratories Managing Director
5. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
9. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. NeurogesX Appoints New Director to the Board